Isoprenoid biosynthesis in Plasmodium falciparum

• Published in: Eukaryotic cell Vol. 13; no. 11; pp. 1348 - 1359
• Main Authors: Guggisberg, Ann M, Amthor, Rachel E, Odom, Audrey R
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01-11-2014
• Subjects: Antimalarials - pharmacology; Fosfomycin - analogs & derivatives; Fosfomycin - pharmacology; Malaria, Falciparum - drug therapy; Malaria, Falciparum - parasitology; Minireview; Plasmodium falciparum; Plasmodium falciparum - metabolism; Terpenes - metabolism
• ISSN: 1535-9778; 1535-9786
• DOI: 10.1128/ec.00160-14

Malaria kills nearly 1 million people each year, and the protozoan parasite Plasmodium falciparum has become increasingly resistant to current therapies. Isoprenoid synthesis via the methylerythritol phosphate (MEP) pathway represents an attractive target for the development of new antimalarials. The phosphonic acid antibiotic fosmidomycin is a specific inhibitor of isoprenoid synthesis and has been a helpful tool to outline the essential functions of isoprenoid biosynthesis in P. falciparum. Isoprenoids are a large, diverse class of hydrocarbons that function in a variety of essential cellular processes in eukaryotes. In P. falciparum, isoprenoids are used for tRNA isopentenylation and protein prenylation, as well as the synthesis of vitamin E, carotenoids, ubiquinone, and dolichols. Recently, isoprenoid synthesis in P. falciparum has been shown to be regulated by a sugar phosphatase. We outline what is known about isoprenoid function and the regulation of isoprenoid synthesis in P. falciparum, in order to identify valuable directions for future research.